iCAD to Highlight Xoft System to Treat Skin, Breast and Gynecological Cancers at ASTRO

ASTRO Booth Number 2449--iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that its Xoft subsidiary will be showcasing its Xoft^® Axxent^® Electronic Brachytherapy System^® at the American Society for Radiation Oncology’s (ASTRO) 55^th Annual Meeting being held from September 22-25, 2013 in Atlanta at booth #2449. The Xoft System can be used to treat non-melanoma skin cancer (NMSC), early-stage breast cancer with Intraoperative Radiation Therapy (IORT) and Accelerated Partial Breast Irradiation (APBI), vaginal, endometrial and cervical cancer.

“This year’s activities at ASTRO demonstrate iCAD’s commitment to delivering targeted, innovative and cost-effective radiation therapy solutions to radiation oncologists to help them to more effectively treat a variety of cancers,” said Ken Ferry, President and CEO of iCAD. “It’s an exciting time for iCAD with new product introductions, significant progress in our post-market breast cancer study, and the presentation of longer term clinical data that supports the increased momentum of our NMSC application.”

The Company’s technology will be featured in the following educational sessions and at the Company’s booth:

About ASTRO

Radiation oncologists, medical physicists, dosimetrists, radiation therapists, radiation oncology nurses and nurse practitioners, biologists, physician assistants and practice administrators comprise ASTRO’s nearly 10,000 members, making it the largest radiation oncology organization of its kind. These medical professionals, found at hospitals, cancer treatment centers and academic research facilities around the globe, make up the radiation therapy treatment teams that are critical in the fight against cancer. Together, these teams, treat more than 1 million cancer patients each year.

ASTRO provides members with the continuing medical education, health policy analysis, patient information resources and advocacy that they need to succeed in today’s ever-changing health care delivery system.

About Xoft Axxent Electronic Brachytherapy System

The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early stage breast cancer, endometrial cancer, cervical cancer and skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. A post-market study is underway to assess the safety and efficacy of Intraoperative Radiation Therapy with the Xoft System. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com.

About iCAD, Inc.

iCAD is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer, cervical cancer and endometrial cancer. For more information, call 877-iCADnow, or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company’s ability to defend itself in litigation matters, the Company’s ability to identify a replacement for the Axxent FlexiShield Mini, the risks relating to the Company’s acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCAD’s and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction, the risks of uncertainty of patent protection; the impact of supply and manufacturing constraints or difficulties; product market acceptance; possible technological obsolescence; increased competition; customer concentration; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.